Introduction: Subcutaneous atezolizumab is approved for the treatment of various solid tumors. Previous results from the IMscin001 study (NCT03735121) demonstrated that the pharmacokinetics, efficacy, immunogenicity, and safety of subcutaneous and intravenous atezolizumab were consistent (data cutoff: April 26, 2022). We present updated data from this trial (data cut-off: 16 January 2023).
Methods: Eligible patients aged ≥18 years with locally advanced/metastatic NSCLC were randomized (2:1) to receive atezolizumab subcutaneously (1875 mg, n=247) or intravenously (1200 mg, n=124) every 3 weeks. Here we present updated efficacy (overall survival [OS]; progression-free survival; objective response rate; duration of response), safety, and immunogenicity endpoints, alongside patient-reported outcomes (PROs) and healthcare practitioner (HCP) perspectives.
Results: In this updated analysis, the median survival follow-up was 9.5 months. Median subcutaneous injection time was 7.1 minutes, with an average subcutaneous injection time of 4-8 minutes in most patients (75.7%). OS data were mature: median OS was similar between treatment arms, at 10.7 and 10.1 months in the subcutaneous and intravenous arms, respectively (HR: 0.88; 95% CI: 0.67-1.16). Other efficacy endpoints, as well as immunogenicity, PROs, and safety, were similar between arms. Most HCPs found subcutaneous administration convenient (79.5%), easy to administer (89.7%), and were satisfied with the treatment (84.6%); 75.0% of HCPs agreed that administering atezolizumab subcutaneously compared with intravenously could save time.
Conclusions: In this analysis, mature OS data were similar between treatments. The updated efficacy and safety profile of subcutaneous atezolizumab is consistent with previous findings and equivalent to intravenous atezolizumab.
Keywords: IMscin001; NSCLC; atezolizumab; intravenous; subcutaneous.
Copyright © 2024. Published by Elsevier Inc.